©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2015; 7(3): 498-506
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.498
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.498
MiR-122 in hepatitis B virus and hepatitis C virus dual infection
Kyoungsub Song, Chang Han, Srikanta Dash, Tong Wu, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, United States
Luis A Balart, Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, United States
Author contributions: Wu T designed the review objective and the review structure; Song K and Wu T collected the reference and wrote the manuscript; Han C, Dash S and Balart LA read through the paper and contributed edition of the manuscript.
Supported by Grants from NIDDK and NCI.
Conflict-of-interest: The authors declare no conflict of interest.
Correspondence to: Tong Wu, MD, PhD, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL-79, New Orleans, LA 70112, United States. twu@tulane.edu
Telephone: +1-504-9885210 Fax: +1-504-9887862
Received: July 16, 2014
Peer-review started: July 16, 2014
First decision: August 28, 2014
Revised: September 6, 2014
Accepted: December 16, 2014
Article in press: December 16, 2014
Published online: March 27, 2015
Processing time: 258 Days and 13 Hours
Peer-review started: July 16, 2014
First decision: August 28, 2014
Revised: September 6, 2014
Accepted: December 16, 2014
Article in press: December 16, 2014
Published online: March 27, 2015
Processing time: 258 Days and 13 Hours
Core Tip
Core tip: This paper summarizes direct and indirect interactions between hepatitis B virus (HBV) and hepatitis C virus (HCV), and the pathobiological role and therapeutic potential of liver specific miR-122 in HBV/HCV dual infection.